Open AccessJS001, an anti-PD-1 mAb for advanced triple negative breast cancer patients after multi-line systemic therapy in a phase I trial
Author(s) -
Li Bian,
Huiqiang Zhang,
Tao Wang,
Shaohua Zhang,
Haifeng Song,
Mingli Xu,
Sheng Yao,
Zefei Jiang
Publication year - 2019
Publication title -
annals of translational medicine
Language(s) - English
Resource type - Journals
eISSN - 2305-5847
pISSN - 2305-5839
DOI - 10.21037/atm.2019.09.08
Subject(s) - medicine , rash , tolerability , triple negative breast cancer , refractory (planetary science) , breast cancer , gastroenterology , cohort , adverse effect , oncology , surgery , cancer , physics , astrobiology
JS001 exhibited a favorable safety profile in advanced TNBC patients who are refractory to multi-line systemic therapy. JS001 also showed a moderate response in these TNBC patients who had limited treatment options.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom